Immuno-Oncology | Specialty

"Advancing Hope": SITC Designs Innovative Educational Experience for the Management of NSCLC

November 23rd 2016

Lung cancer alone accounts for 26.5% of all cancer-related mortalities in the United States, which is more than any other malignancy. Despite increased awareness that smoking is an important risk factor for lung cancer, which has reduced the number of smokers in the U.S., nearly a quarter of a million new diagnoses are expected in 2016.

Looming Questions, Challenges Facing Physicians in Prostate Cancer

November 22nd 2016

Identifying biomarkers to determine who should receive chemotherapy, targeted agents, and immunotherapy is just one of several obstacles the prostate cancer community is currently facing.

I-SPY 2 Paves the Way for Novel HER2-Targeted Agents in Breast Cancer

November 22nd 2016

There are a wide variety of novel agents currently being investigated in the neoadjuvant setting for patients with HER2-positive breast cancer.

Birrer Assesses Current Challenges in Cervical Cancer

November 21st 2016

Oncologists continue to face several challenges when it comes to the prevention and treatment of cervical cancer, according to Michael Birrer, MD, PhD.

Nivolumab/Radiotherapy Combo Well-Tolerated in Newly Diagnosed GBM

November 20th 2016

Treatment with nivolumab and radiotherapy with or without concurrent temozolomide was well tolerated and showed promising signs of efficacy for patients with newly-diagnosed glioblastoma multiforme.

Pembrolizumab Shows Durable Benefit for PD-L1-Positive Recurrent GBM

November 19th 2016

Pembrolizumab had a 6-month progression-free survival rate of 44% and a manageable safety profile for patients with recurrent PD-L1-positive glioblastoma multiforme.

Dr. Reardon on the KEYNOTE-028 Trial of Pembrolizumab for GBM

November 19th 2016

Checkpoint Inhibitors Show Promise in Glioblastoma

November 19th 2016

Findings from the phase II trials KEYNOTE-028 of pembrolizumab and MEDI4736 (durvalumab) point to a role for checkpoint inhibitors in the treatment of glioblastoma multiforme, based on encouraging efficacy signals and safety data with the two agents.

Dr. Tripathy on Immunotherapy Potential in HER2-Positive Breast Cancer

November 19th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the potential role of immunotherapy in the treatment of patients with HER2-positive breast cancer.

Immunotherapy Becomes Mainstay in Bladder Cancer Care

November 19th 2016

The PD-1/PD-L1 inhibitors moving through the pipeline in bladder cancer will have a lasting impact on the armamentarium in the field, explains Jonathan E. Rosenberg, MD.

Vokes on Increasing Impact of Immunotherapy in Head and Neck Cancer

November 18th 2016

As immunotherapy continues to make headway in several different cancer types, these agents are only just arriving to the treatment landscape of head and neck cancer.

Expert Anticipates Avalanche of Data to Impact Treatment Landscape in NSCLC

November 18th 2016

Treatment in lung cancer continues to evolve at a rapid pace with the arrival of a set of efficacious new agents and promising evidence-based data. According to Corey J. Langer, MD, a veritable avalanche of additional data is on the way.

Dr. Iyer on Advice for Physicians Using Immunotherapy in Bladder Cancer

November 18th 2016

Gopa Iyer, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses significant points for community oncologists to be aware of when treating patients with bladder cancer with immunotherapy agents.

New Options Emerge in Frontline, Adjuvant RCC Care

November 17th 2016

Therapeutic options for patients with renal cell carcinoma have increased rapidly in the past decade, yet the field is still poised to expand significantly in the coming years, said Robert S. Alter, MD.

Pembrolizumab's Big Win in Immunotherapy Battle for Frontline in Lung Cancer

November 17th 2016

It has been about 18 months since the first immunotherapy checkpoint agent was approved for patients with non–small cell lung cancer. Now there are 3 monoclonal antibodies that target the PD-1/PD-L1 pathway on the market for the tumor type and the focus has shifted rapidly to establishng immunotherapy as a new frontline standard.

Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

November 17th 2016

​Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.

Dr. Suzanne L. Topalian on Immunotherapy Biomarkers in CRC

November 17th 2016

Suzanne L. Topalian, MD, professor of Surgery, Johns Hopkins Medicine, discuses novel immunotherapy biomarkers in colorectal cancer (CRC).

Biomarker Development Key to Optimizing Immunotherapy in Lung Cancer

November 17th 2016

The expression of PD-L1 has been at the forefront of biomarker development for PD-1/PD-L1 inhibitors, but there is much uncertainty surrounding its use and other biomarkers are needed.

Dr. Goldberg on PD-L1 as a Biomarker in Lung Cancer

November 17th 2016

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses the use of PD-L1 as a biomarker in treating patients with lung cancer.

Improved Patient Selection Needed to Advance HER2+ Breast Cancer Care

November 17th 2016

Immunotherapy and chemotherapy are options physicians should not dismiss for patients with HER2-positive breast cancer, according to Lisa Carey, MD, even with the available targeted agents trastuzumab, pertuzumab, lapatinib, and ado-trastuzumab emtansine.